Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Executive Summary

A biosimilar of Amgen's Neulasta appears on track for FDA approval by the June 4 action date, management said during an investor briefing that showcased Mylan's expansive biosimilar pipeline. Mid- to late-stage copies of products like Advair, Symbicort, Herceptin, Humira, Avastin, Rituxan, Eylea and Botox highlight the strategic direction Mylan moved in nearly a decade ago. 

Advertisement

Related Content

Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Mylan Looks To Expedite Biosimilar Humira in EU Through Kyowa Deal
Mylan Set To Develop Biosimilar Botox In Deal With Revance
Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC122891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel